GlassScriptPhysician profile
Anna V Mussone
NPI 1528314812
$6,453.79
in general payments reported to CMS, 2019-2025
28 companies · $1,891 in 2025
The $1,891 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $1,464 · 2023: $1,333 · 2024: $1,361 · 2025: $1,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,585.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $1,250.19 | 2022-2025 | Barostim Neo System |
| Amgen INC. | $768.48 | 2021-2025 | Repatha, Repatha |
| Medtronic, INC. | $562.21 | 2022-2024 | Corevalve Evolut R, Harmony |
| Atricure, INC. | $469.06 | 2022-2025 | Epi-Ease Epicardial Access System, Atriclip Laa Exclusion System, Synergy Ablation System |
| Impulse Dynamics (USA) INC. | $349.84 | 2022-2025 | Optimizer, Optimizer |
| Novartis Pharmaceuticals Corporation | $339.60 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $310.82 | 2021-2022 | |
| Pfizer INC. | $268.64 | 2022-2025 | |
| Abbott Laboratories | $261.24 | 2022-2025 | Amplatzer Amulet |
| Kestra Medical Technology Services, INC. | $256.75 | 2024-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $236.91 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $232.41 | 2021-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $205.43 | 2025 | Uptravi, Opsumit |
| Abiomed | $156.89 | 2024-2025 | Impella |
| Scpharmaceuticals INC. | $134.61 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.34 | 2024 | Jardiance |
| Novo Nordisk INC | $109.34 | 2025 | Ozempic |
| Boston Scientific Corporation | $84.79 | 2022-2025 | General - Therapies, Ekosonic, Eluvia |
| Bayer Healthcare Pharmaceuticals INC. | $65.83 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.11 | 2024-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $53.21 | 2023-2025 | Onpattro, Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $51.25 | 2024 | Arcalyst |
| Zoll Respicardia, INC. | $24.81 | 2025 | Remede System |
| Esperion Therapeutics, INC. | $19.08 | 2024 | Nexletol |
| Irhythm Technologies, INC. | $18.92 | 2024 | Zio Monitor, Zio Xt Patch |
| Astrazeneca Pharmaceuticals LP | $18.62 | 2023 | Farxiga |
| Bard Peripheral Vascular, INC. | $17.41 | 2024 | Crosser Iq |
| Vivaquant INC, Dba Rhythm Express | $12.00 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Mussone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.